

# GEN Biotechnology

CALL FOR PAPERS

**GEN Biotechnology** is the new marquee peer-reviewed journal launching in early 2022, publishing exceptional groundbreaking research across all aspects of biotechnology.

A truly multidisciplinary journal, **GEN Biotechnology** will validate and showcase advances in technology development and scientific and medical applications. In addition to original research, each issue will include a rich array of news, insights, analysis and KOL commentary from GEN's expert journalists and correspondents, and from active researchers.

**GEN Biotechnology** will be an essential journal for the booming biotechnology industry worldwide. It harnesses the expertise of *Genetic Engineering & Biotechnology News (GEN)*, which has covered the biotech industry for 40 years, and GEN's publisher **Mary Ann Liebert, Inc.**, which publishes 100 peer-reviewed titles, including *Human Gene Therapy*, *Stem Cells and Development*, and *The CRISPR Journal*.

This is your best chance to be part of the inaugural issue, publishing in early 2022. **Please submit your paper today!** Topics of consideration include, but are not limited to:

- ♦ Drug discovery
- ♦ Cell and gene therapy
- ♦ Immunotherapy
- ♦ Genome editing
- ♦ Genomics
- ♦ AI/Data
- ♦ Bio-engineering
- ♦ Neuroscience
- ♦ Cancer research
- ♦ Diagnostics
- ♦ Translational research
- ♦ Multiomics
- ♦ Agbiotech
- ♦ Environmental Biotechnology
- ♦ Precision medicine
- ♦ Single-cell biology
- ♦ New methods

**GEN Biotechnology** has assembled an outstanding diverse international team of editorial advisors providing expertise across the broad spectrum of biotechnology disciplines. A chief editor will be named shortly. The editorial team is committed to providing rapid, constructive peer review, and prompt decisions. The group of professional editors is led by **Dr. Kevin Davies** (founding editor *Nature Genetics*, Executive Editor *GEN Biotechnology*) and **Dr. Fay Lin** (Senior Editor).

**GEN Biotechnology** will be published bimonthly online and in print. As a hybrid journal, authors will be able to take advantage of several open access options if they (or their funders) desire. Accepted research articles will be published online ahead of print. Naturally, authors submitting manuscripts early will have a better chance of being included in the coveted debut issue.

## Instructions for Authors

## Submit Now



@GENBiotechJrnl

**Questions?** Please contact **Dr. Kevin Davies** (Executive Editor) for more information. Benefits of publishing in **GEN Biotechnology** include:

- ♦ Fast and user-friendly electronic submission
- ♦ Rapid and constructive peer review
- ♦ Expedited publication in launch issue and beyond
- ♦ Open Access options available
- ♦ High visibility reaching researchers in every facet of the biotech community
- ♦ Maximum exposure: accessible in 170 countries worldwide



Cover art credit:  
Eliza Wolfson